TABLE 3.

Gout-Specific Cost and Utilization in the Post-match Sample, Unadjusted^a

	Allopurinol (n = 1,486)		Febuxostat (n = 1,486)		P Value
Gout-specific utilization
Hospitalization, any (n, %)	62	4.2	58	3.9	0.709
Repeat hospitalization (n, %)	5	0.3	6	0.4	0.763
Mean [SD] hospitalizations per month	0.01	[0.05]	0.01	[0.05]	0.813
Mean [SD] length of stay, hospitalizations	4.23	[3.17]	5.39	[5.14]	< 0.001
Office visit, any (n, %)	904	60.8	929	62.5	0.346
Mean [SD] office visits per month	0.26	[0.43]	0.25	[0.38]	0.846
ER visit, any (n, %)	69	4.6	74	5.0	0.668
Mean [SD] ER visits per month	0.03	[0.26]	0.04	[0.24]	0.877
Mean [SD] gout-specific cost per month, $
Hospitalization, any	20	[269]	24	[198]	0.688
Repeat hospitalization	113	[626]	131	[449]	0.372
Office visit, any	11	[29]	12	[23]	0.786
Repeat office visits	19	[35]	19	[26]	0.936
ER visit, any	2	[22]	3	[22]	0.833
Repeat ER visits	53	[90]	53	[83]	0.959
Prescription drug	33	[72]	195	[132]	< 0.001
Allopurinol	5	[3]	NA	NA	NA
Febuxostat	NA	NA	168	[105]	NA
Other gout-specific prescription drugs	28	[71]	27	[63]	0.912
Total costs	87	[389]	243	[265]	< 0.001

^aGout-specific cost is reported in 2012 U.S. dollars and is defined to include 100% of gout-specific procedures and/or medications and the relevant proportion as per the protocol of any other service with a gout diagnosis.

ER = emergency room; NA = not applicable; SD = standard deviation.